KANT
Price
$0.30
Change
+$0.02 (+7.14%)
Updated
Jun 25 closing price
Capitalization
4.02M
MDGL
Price
$299.89
Change
+$22.25 (+8.01%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
6.16B
41 days until earnings call
Interact to see
Advertisement

KANT vs MDGL

Header iconKANT vs MDGL Comparison
Open Charts KANT vs MDGLBanner chart's image
Kineta
Price$0.30
Change+$0.02 (+7.14%)
Volume$44.11K
Capitalization4.02M
Madrigal Pharmaceuticals
Price$299.89
Change+$22.25 (+8.01%)
Volume$3.67K
Capitalization6.16B
KANT vs MDGL Comparison Chart in %
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KANT vs. MDGL commentary
Jun 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KANT is a Hold and MDGL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 26, 2025
Stock price -- (KANT: $0.30 vs. MDGL: $277.64)
Brand notoriety: KANT and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KANT: 237% vs. MDGL: 51%
Market capitalization -- KANT: $4.02M vs. MDGL: $6.16B
KANT [@Biotechnology] is valued at $4.02M. MDGL’s [@Biotechnology] market capitalization is $6.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $312.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KANT’s FA Score shows that 1 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • KANT’s FA Score: 1 green, 4 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than KANT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 4 TA indicator(s) are bullish.

  • MDGL’s TA Score: 4 bullish, 5 bearish.

Price Growth

KANT (@Biotechnology) experienced а +10.09% price change this week, while MDGL (@Biotechnology) price change was -1.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.00%. For the same industry, the average monthly price growth was +32.55%, and the average quarterly price growth was +15.13%.

Reported Earning Dates

KANT is expected to report earnings on May 15, 2025.

MDGL is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+2.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.17B) has a higher market cap than KANT($4.03M). MDGL YTD gains are higher at: -10.024 vs. KANT (-15.108). KANT has higher annual earnings (EBITDA): -20.45M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. KANT (900K). KANT has less debt than MDGL: KANT (710K) vs MDGL (120M). MDGL has higher revenues than KANT: MDGL (317M) vs KANT (0).
KANTMDGLKANT / MDGL
Capitalization4.03M6.17B0%
EBITDA-20.45M-376.15M5%
Gain YTD-15.108-10.024151%
P/E RatioN/AN/A-
Revenue0317M-
Total Cash900K843M0%
Total Debt710K120M1%
FUNDAMENTALS RATINGS
KANT vs MDGL: Fundamental Ratings
KANT
MDGL
OUTLOOK RATING
1..100
86
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
63
Fair valued
PROFIT vs RISK RATING
1..100
10047
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6459
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KANT's Valuation (27) in the null industry is somewhat better than the same rating for MDGL (63) in the Pharmaceuticals Other industry. This means that KANT’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (47) in the Pharmaceuticals Other industry is somewhat better than the same rating for KANT (100) in the null industry. This means that MDGL’s stock grew somewhat faster than KANT’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as KANT (100) in the null industry. This means that MDGL’s stock grew similarly to KANT’s over the last 12 months.

MDGL's Price Growth Rating (59) in the Pharmaceuticals Other industry is in the same range as KANT (64) in the null industry. This means that MDGL’s stock grew similarly to KANT’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as KANT (100) in the null industry. This means that MDGL’s stock grew similarly to KANT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGL
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 7 days ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DRSK28.360.12
+0.42%
Aptus Defined Risk ETF
IWV344.970.20
+0.06%
iShares Russell 3000 ETF
MVF6.55-0.02
-0.30%
BlackRock MuniVest Fund
XHE80.61-0.34
-0.42%
SPDR® S&P Health Care Equipment ETF
FLQS40.54-0.47
-1.14%
Franklin US Small Cap Mltfctr Idx ETF

KANT and

Correlation & Price change

A.I.dvisor indicates that over the last year, KANT has been loosely correlated with MDGL. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if KANT jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KANT
1D Price
Change %
KANT100%
+6.66%
MDGL - KANT
62%
Loosely correlated
-2.58%
SLNO - KANT
45%
Loosely correlated
+1.92%
VKTX - KANT
35%
Loosely correlated
+0.52%
CELC - KANT
34%
Loosely correlated
-2.47%
MDWD - KANT
29%
Poorly correlated
-0.10%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-2.58%
KANT - MDGL
62%
Loosely correlated
+6.66%
ALXO - MDGL
56%
Loosely correlated
-0.44%
ZNTL - MDGL
51%
Loosely correlated
-2.96%
CGEM - MDGL
50%
Loosely correlated
+1.02%
NAGE - MDGL
44%
Loosely correlated
-5.10%
More